An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency

Trial Profile

An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Feb 2015

At a glance

  • Drugs Sugammadex (Primary)
  • Indications Neuromuscular blockade
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Apr 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 06 Mar 2014 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.
    • 17 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top